Učitavanje...
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
OBJECTIVE: The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have resp...
Spremljeno u:
| Izdano u: | Pharmacoeconomics |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5999172/ https://ncbi.nlm.nih.gov/pubmed/29797187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0674-x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|